Latest News

New research highlights the efficacy and safety of HRS-1780, an investigational nonsteroidal MRA, in treating chronic kidney disease (CKD).

A long-term study reveals that high-fat cheese consumption may lower dementia risk, challenging traditional views on dietary fat and brain health.

Prolonged exposure to specific air pollution components significantly increases depression risk in older adults, highlighting the need for targeted regulations.

Research reveals that wildfire smoke exposure significantly impacts pediatric asthma control in the Northeast US, highlighting urgent climate health concerns.

Research reveals that adults who were hospitalized with RSV experience significant long-term health issues, impacting quality of life and physical function.

Pharmacists must adapt to the evolving landscape of psychedelic therapies, focusing on education, patient support, and understanding regulatory challenges.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

There are many challenges with access to immunomodulatory drugs in multiple myeloma that pharmacists can play a pivotal role in overcoming.

New research explores the gut-brain connection, suggesting that improving gut health may enhance mental well-being.

A promising multistage malaria vaccine shows potential for broader protection against the disease, highlighting the evolving role of pharmacists in vaccination efforts.

High levels of C-reactive protein in the blood and lower heart rate variability were linked to cardiovascular events in patients with depression, anxiety, or both.

The FDA approved mitapivat, the first oral therapy for thalassemia anemia, offering hope for patients with transfusion-dependent and non–transfusion-dependent forms.

FDA approves mosunetuzumab's subcutaneous formulation, enhancing treatment access for relapsed follicular lymphoma.

Narsoplimab gains FDA approval for treating transplant-associated thrombotic microangiopathy, showing promising survival rates in high-risk patients.

Lowering blood glucose levels significantly reduces heart disease risks in prediabetes, offering new hope for prevention and management strategies.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

The FDA's 2025 biosimilar approvals enhanced treatment options for chronic diseases, improving accessibility and affordability for patients and health care providers.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

Medication errors are major public health issues, disproportionately affecting populations such as children, Ooder adults, and those with limited health literacy.

FDA approves lumateperone as a new adjunct therapy for major depressive disorder, offering hope for those with persistent symptoms despite treatment.